Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Capecitabine-Induced Sarcoidosis

  • Received : 2012.01.12
  • Accepted : 2012.01.27
  • Published : 2012.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Sarcoidosis is an inflammatory disease involving multiple-organs with an unknown cause. The new onset of sarcoidosis associated with therapeutic agents has been observed in 3 clinical settings; tumor necrosis factor antagonists in autoimmune rheumatologic diseases, interferon alpha with or without ribavirin in patients with chronic hepatitis C or melanoma, and antineoplastic agent-associated sarcoidosis in patients with hematologic malignancies. Here, we report a female patient who developed sarcoidosis after capecitabine treatment as an adjuvant chemotherapy for sigmoid colon cancer. To our knowledge, this is the first report of a capecitabine-induced sarcoidosis.

Keywords

References

  1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-81.
  2. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011;139:174-82.
  3. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004;170: 1324-30.
  4. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164(10 Pt 1):1885-9.
  5. Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin Drug Saf 2010;9:831-41.
  6. Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 2010;16:274-9.
  7. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011;124:386-94.
  8. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69-80.
  9. Gayet AR, Plaisance P, Bergmann JF, Mouly S. Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-{alpha}2a and ribavirin: a case report and literature review. Clin Med Res 2010;8:163-7.
  10. Heinzerling LM, Anliker MD, Muller J, Schlaeppi M, von Moos R. Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 2010;33: 834-9.
  11. Lopez V, Molina I, Monteagudo C, Jorda E. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature. Int J Dermatol 2011;50:287-91.
  12. Papanikolaou IC, Sharma OP. The relationship between sarcoidosis and lymphoma. Eur Respir J 2010;36: 1207-9.
  13. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007;25:326-33.
  14. Yao M, Funk GF, Goldstein DP, DeYoung BR, Graham MM. Benign lesions in cancer patients: Case 1 Sarcoidosis after chemoradiation for head and neck cancer. J Clin Oncol 2005;23:640-1.
  15. Kim DS. Sarcoidosis in Korea: report of the Second Nationwide Survey. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:176-80.

Cited by

  1. Capecitabine : First report of sarcoidosis: case report vol.1431, pp.1, 2012, https://doi.org/10.1007/s40278-012-0036-y
  2. A Case of Abdominal Sarcoidosis in a Patient with Acute Myeloid Leukemia vol.2013, pp.None, 2013, https://doi.org/10.1155/2013/379898